Eleftherios P Mamounas1, Qing Liu1, Soonmyung Paik1, Frederick L Baehner1, Gong Tang1, Jong-Hyeon Jeong1, S Rim Kim1, Steven M Butler1, Farid Jamshidian1, Diana B Cherbavaz1, Amy P Sing1, Steven Shak1, Thomas B Julian1, Barry C Lembersky1, D Lawrence Wickerham1, Joseph P Costantino1, Norman Wolmark1. 1. Affiliations of authors: National Surgical Adjuvant Breast and Bowel Project (NSABP Legacy trials are now a part of the NRG Oncology portfolio), Pittsburgh, PA (EPM, SP, SRK, TBJ, BCL, DLW, NW); UF Health Cancer Center at Orland Health, Orlando, FL (EPM); NRG Oncology, Pittsburgh, PA (QL, GT, JHJ, JPC); University of Pittsburgh, Pittsburgh, PA (QL, GT, JHJ, JPC); Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea (SP); Genomic Health, Inc., Redwood City, CA (FLB, SMB, FJ, DBC, APS, SS); Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA (TBJ, DLW, NW); University of Pittsburgh Medical Center, Pittsburgh, PA (BCL).
Abstract
Background: The 21-gene recurrence score (RS) predicts risk of locoregional recurrence (LRR) in node-negative, estrogen receptor (ER)-positive breast cancer. We evaluated the association between RS and LRR in node-positive, ER-positive patients treated with adjuvant chemotherapy plus tamoxifen in National Surgical Adjuvant Breast and Bowel Project B-28. Methods: B-28 compared doxorubicin/cyclophosphamide (AC X 4) with AC X 4 followed by paclitaxel X 4. Tamoxifen was given to patients age 50 years or older and those younger than age 50 years with ER-positive and/or progesterone receptor-positive tumors. Lumpectomy patients received breast radiotherapy. Mastectomy patients received no radiotherapy. The present study includes 1065 ER-positive, tamoxifen-treated patients with RS assessment. Cumulative incidence functions and subdistribution hazard regression models were used for LRR to account for competing risks including distant recurrence, second primary cancers, and death from other causes. Median follow-up was 11.2 years. All statistical tests were one-sided. Results: There were 80 LRRs (7.5%) as first events (68% local/32% regional). RS was low: 36.2%; intermediate: 34.2%; and high: 29.6%. RS was a statistically significant predictor of LRR in univariate analyses (10-year cumulative incidence of LRR = 3.3%, 7.2%, and 12.2% for low, intermediate, and high RS, respectively, P < .001). In multivariable regression analysis, RS remained an independent predictor of LRR (hazard ratio [HR] = 2.59, 95% confidence interval [CI] = 1.28 to 5.26, for a 50-point difference, P = .008) along with pathologic nodal status (HR = 1.91, 95% CI = 1.20 to 3.03, for four or more vs one to three positive nodes, P = .006) and tumor size (HR = 1.28, 95% CI = 1.05 to 1.55, for a 1 cm difference, P = .02). Conclusions: RS statistically significantly predicts risk of LRR in node-positive, ER-positive breast cancer patients after adjuvant chemotherapy plus tamoxifen. These findings can help in the selection of appropriate candidates for comprehensive radiotherapy.
RCT Entities:
Background: The 21-gene recurrence score (RS) predicts risk of locoregional recurrence (LRR) in node-negative, estrogen receptor (ER)-positive breast cancer. We evaluated the association between RS and LRR in node-positive, ER-positive patients treated with adjuvant chemotherapy plus tamoxifen in National Surgical Adjuvant Breast and Bowel Project B-28. Methods: B-28 compared doxorubicin/cyclophosphamide (AC X 4) with AC X 4 followed by paclitaxel X 4. Tamoxifen was given to patients age 50 years or older and those younger than age 50 years with ER-positive and/or progesterone receptor-positive tumors. Lumpectomy patients received breast radiotherapy. Mastectomy patients received no radiotherapy. The present study includes 1065 ER-positive, tamoxifen-treated patients with RS assessment. Cumulative incidence functions and subdistribution hazard regression models were used for LRR to account for competing risks including distant recurrence, second primary cancers, and death from other causes. Median follow-up was 11.2 years. All statistical tests were one-sided. Results: There were 80 LRRs (7.5%) as first events (68% local/32% regional). RS was low: 36.2%; intermediate: 34.2%; and high: 29.6%. RS was a statistically significant predictor of LRR in univariate analyses (10-year cumulative incidence of LRR = 3.3%, 7.2%, and 12.2% for low, intermediate, and high RS, respectively, P < .001). In multivariable regression analysis, RS remained an independent predictor of LRR (hazard ratio [HR] = 2.59, 95% confidence interval [CI] = 1.28 to 5.26, for a 50-point difference, P = .008) along with pathologic nodal status (HR = 1.91, 95% CI = 1.20 to 3.03, for four or more vs one to three positive nodes, P = .006) and tumor size (HR = 1.28, 95% CI = 1.05 to 1.55, for a 1 cm difference, P = .02). Conclusions: RS statistically significantly predicts risk of LRR in node-positive, ER-positive breast cancerpatients after adjuvant chemotherapy plus tamoxifen. These findings can help in the selection of appropriate candidates for comprehensive radiotherapy.
Authors: J Ragaz; S M Jackson; N Le; I H Plenderleith; J J Spinelli; V E Basco; K S Wilson; M A Knowling; C M Coppin; M Paradis; A J Coldman; I A Olivotto Journal: N Engl J Med Date: 1997-10-02 Impact factor: 91.245
Authors: Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark Journal: N Engl J Med Date: 2004-12-10 Impact factor: 91.245
Authors: Irene L Wapnir; Stewart J Anderson; Eleftherios P Mamounas; Charles E Geyer; Jong-Hyeon Jeong; Elizabeth Tan-Chiu; Bernard Fisher; Norman Wolmark Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Lawrence J Solin; Robert Gray; Lori J Goldstein; Abram Recht; Frederick L Baehner; Steven Shak; Sunil Badve; Edith A Perez; Lawrence N Shulman; Silvana Martino; Nancy E Davidson; George W Sledge; Joseph A Sparano Journal: Breast Cancer Res Treat Date: 2012-05-01 Impact factor: 4.872
Authors: M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler Journal: N Engl J Med Date: 1997-10-02 Impact factor: 91.245
Authors: Minji Koh; Jinhong Jung; Su Ssan Kim; Seung Do Ahn; Eun Kyung Choi; Il Yong Chung; Jong Won Lee; Sung-Bae Kim; Jae Ho Jeong Journal: Breast Cancer Res Treat Date: 2021-04-23 Impact factor: 4.872
Authors: Katya Losk; Rachel A Freedman; Alison Laws; Olga Kantor; Elizabeth A Mittendorf; Zhenying Tan-Wasielewski; Lorenzo Trippa; Nancy U Lin; Eric P Winer; Tari A King Journal: Breast Cancer Res Treat Date: 2020-09-16 Impact factor: 4.872
Authors: Yunan Han; Zhi-Feng Miao; Min Lian; Lindsay L Peterson; Graham A Colditz; Ying Liu Journal: Breast Cancer Res Treat Date: 2020-09-14 Impact factor: 4.872
Authors: Andreana N Holowatyj; Michele L Cote; Julie J Ruterbusch; Kristina Ghanem; Ann G Schwartz; Fawn D Vigneau; David H Gorski; Kristen S Purrington Journal: J Clin Oncol Date: 2018-01-17 Impact factor: 44.544
Authors: David Krug; René Baumann; Wilfried Budach; Marciana Nona Duma; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Thomas Hehr; Marc D Piroth; Felix Sedlmayer; Rainer Souchon; Frederik Wenz; Rolf Sauer Journal: Breast Care (Basel) Date: 2020-01-24 Impact factor: 2.860